Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

RIVASTIGMINE vs ROFLUMILAST: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

RIVASTIGMINE vs ROFLUMILAST: Safety Overview

Metric RIVASTIGMINE ROFLUMILAST
Total FAERS Reports 9,123 2,700
Deaths Reported 2,232 645
Death Rate 24.5% 23.9%
Hospitalizations 2,716 625
Average Patient Age 80.0 yrs 68.8 yrs
% Female Patients 59.5% 56.3%
FDA Approval Date Apr 21, 2000 Apr 17, 2023
Manufacturer Novartis Pharmaceuticals Corporation Aurobindo Pharma Limited
Route TRANSDERMAL ORAL
Marketing Status Discontinued Prescription